Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | GZ17-6.02 |
Synonyms | |
Therapy Description |
GZ17-6.02 is a nutraceutical composed of curcumin, harmine, and isovanillin, which may induce apoptosis and decrease viability and migration of tumor cells and reduce tumor growth (PMID: 30111862, PMID: 31951027) |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
GZ17-6.02 | GZ176.02|GZ17 6.02 | GZ17-6.02 is a nutraceutical composed of curcumin, harmine, and isovanillin, which may induce apoptosis and decrease viability and migration of tumor cells and reduce tumor growth (PMID: 30111862, PMID: 31951027) |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT06636123 | Phase I | GZ17-6.02 | GZ17-6.02 in Advanced CRPC After Progression on Anti-Androgen Therapy | Not yet recruiting | USA | 0 |